Citigroup Inc Entrada Therapeutics, Inc. Transaction History

Citigroup Inc

$169 Billion
Q3 2024

A detailed history of Citigroup Inc transactions in Entrada Therapeutics, Inc. stock. As of the latest transaction made, Citigroup Inc holds 17,982 shares of TRDA stock, worth $319,000. This represents 0.0% of its overall portfolio holdings.

Number of Shares

17,982

Previous 5,543 224.41%

Holding current value

$319,000

Previous $78,000 267.95%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	BUY	$13.65 - $17.86 $169,792 - $222,160	12,439 Added 224.41%	17,982 $287,000
Q2 2024 Aug 12, 2024	SELL	$11.85 - $16.45 $601,316 - $834,738	-50,744 Reduced 90.15%	5,543 $78,000
Q1 2024 May 10, 2024	BUY	$11.58 - $17.0 $615,789 - $904,009	53,177 Added 1709.87%	56,287 $797,000
Q4 2023 Feb 09, 2024	BUY	$11.36 - $16.99 $34,977 - $52,312	3,079 Added 9932.26%	3,110 $46,000
Q3 2023 Nov 09, 2023	SELL	$13.61 - $18.01 $90,261 - $119,442	-6,632 Reduced 99.53%	31 $0
Q2 2023 Aug 10, 2023	SELL	$11.02 - $18.01 $610,067 - $997,033	-55,360 Reduced 89.26%	6,663 $100,000
Q1 2023 May 11, 2023	BUY	$9.58 - $16.2 $105,197 - $177,892	10,981 Added 21.51%	62,023 $899,000
Q4 2022 Feb 09, 2023	BUY	$13.52 - $22.89 $668,685 - $1.13 Million	49,459 Added 3124.38%	51,042 $690,000
Q3 2022 Nov 10, 2022	BUY	$9.65 - $15.76 $14,368 - $23,466	1,489 Added 1584.04%	1,583 $25,000
Q2 2022 Aug 10, 2022	SELL	$5.49 - $12.94 $1,751 - $4,127	-319 Reduced 77.24%	94 $1,000
Q1 2022 May 12, 2022	SELL	$7.99 - $16.93 $15,820 - $33,521	-1,980 Reduced 82.74%	413 $4,000
Q4 2021 Feb 10, 2022	BUY	$13.7 - $35.0 $32,784 - $83,755	2,393 New	2,393 $41,000

Others Institutions Holding TRDA

# of Institutions

101

Shares Held

28.1M

Call Options Held

34.5K

Put Options Held

16.4K

View Full List

About Entrada Therapeutics, Inc.

Ticker TRDA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 31,368,500
Market Cap $556M
Description
Entrada Therapeutics, Inc., a biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its endosomal escape vehicle platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. The company's lead product candidate is ENTR-601-44, which is in precli...

More about TRDA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

News

Stay updated on Citigroup Inc with notifications on news.

Account